Symposium on Fundamental Cancer Research最新文献

Retroviruses as tools for mammalian development. 逆转录病毒作为哺乳动物发育的工具。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

R Jaenisch, P Soriano

引用次数: 0

The Drosophila epidermal growth factor receptor homolog: structure, evolution, and possible functions. 果蝇表皮生长因子受体同源物:结构、进化和可能的功能。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

B Z Shilo, E D Schejter, D Segal, D S Ginsberg, L Glazer

{"title":"The Drosophila epidermal growth factor receptor homolog: structure, evolution, and possible functions.","authors":"B Z Shilo, E D Schejter, D Segal, D S Ginsberg, L Glazer","doi":"","DOIUrl":"","url":null,"abstract":"A unique gene termed DER (Drosophila epidermal growth factor [EGF] receptor homolog) was isolated from Drosophila melanogaster and mapped to position 57F on the right arm of the second chromosome. The deduced amino acid sequence showed that the DER protein is 1409 amino acids long. In homology it is similar to the human EGF receptor and to rat and human neu proteins. The most striking difference between the Drosophila and human homologs is DER's additional 166 amino acids. The extra sequence is rich in cysteine residues and is another duplication of one of the two cysteine-rich regions, which are a hallmark of the EGF receptor and related proteins. Analysis of several cDNA clones of DER revealed variability at the 5' end of the coding region, demonstrating the presence of at least three splicing alternatives. All three transcripts have a similar tissue distribution during development: they are uniformly distributed in embryos, localized primarily in proliferating tissues in larvae, and found mainly in the brain cortex and the thoracic and abdominal ganglia in adults. The DER protein thus seems to have multiple roles during development, and it may represent a \"universal\" transducer of signals into the cell.","PeriodicalId":77905,"journal":{"name":"Symposium on Fundamental Cancer Research","volume":"39 ","pages":"87-97"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14253819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phosphatidylinositol kinases and cell transformation. 磷脂酰肌醇激酶与细胞转化。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

L Cantley, M Whitman, D R Kaplan, S B Chahwala, L Fleischman, G Endemann, B S Schaffhausen, T M Roberts

{"title":"Phosphatidylinositol kinases and cell transformation.","authors":"L Cantley, M Whitman, D R Kaplan, S B Chahwala, L Fleischman, G Endemann, B S Schaffhausen, T M Roberts","doi":"","DOIUrl":"","url":null,"abstract":"Products of phosphatidylinositol (PI) turnover have recently been implicated as regulators of cell growth and differentiation. Transformation of cells in culture by infection with certain viruses (Rous sarcoma virus, Kirsten sarcoma virus, and polyoma virus) or by transfection with the oncogenes carried by these viruses affect the steady-state level of intermediates in the PI turnover pathway. In addition, immunoprecipitates of the transforming gene products of Rous sarcoma virus and polyoma virus contain activities of certain enzymes in the PI turnover pathway. We have previously reported that polyoma middle T immunoprecipitates can catalyze phosphorylation of PI to phosphatidylinositol-4-phosphate (PIP). This activity is not intrinsic to middle T or pp60c-src but is due to a cellular enzyme that specifically associates with the middle T/pp60c-src complex. The PI kinase is found in immunoprecipitates of the middle t protein from polyoma viruses that are capable of cell transformation but does not associate with mutants of middle t defective in transformation, suggesting that this association may be important for transformation. Two PI kinases from fibroblasts (type I and type II) that are separable by anion exchange chromatography have been partially purified and characterized. These enzymes differ in their Km for ATP as well as their Ki for adenosine and ADP. Only the type I PI kinase specifically associates with the transformation-competent mutants of middle T.","PeriodicalId":77905,"journal":{"name":"Symposium on Fundamental Cancer Research","volume":"39 ","pages":"165-72"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13965187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proto-oncogene fos: an inducible multifaceted gene. 原癌基因fos:一个可诱导的多面基因。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

R L Mitchell, S K Hanks, I M Verma

引用次数: 0

Critical molecular determinant of carcinogenesis. Proceedings of The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston's Thirty-ninth Symposium on Fundamental Cancer Research. 16-19 September 1986, Houston, Texas. 致癌的关键分子决定因素。1986年9月16-19日，德克萨斯州休斯顿，德克萨斯大学安德森医院和肿瘤研究所第39届基础癌症研究研讨会论文集。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

引用次数: 0

Mutagen-induced antigenic variants of tumor cells. 诱变剂诱导的肿瘤细胞抗原变异。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

T Boon, A Van Pel, E De Plaen, F Vessière

引用次数: 0

Interleukin 2-activated cytotoxic lymphocytes in cancer therapy. 白细胞介素2激活的细胞毒性淋巴细胞在癌症治疗中的作用。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

E A Grimm, S K Jacobs, L A Lanza, G Melin, J A Roth, D J Wilson

{"title":"Interleukin 2-activated cytotoxic lymphocytes in cancer therapy.","authors":"E A Grimm, S K Jacobs, L A Lanza, G Melin, J A Roth, D J Wilson","doi":"","DOIUrl":"","url":null,"abstract":"LAK are cytolytic lymphocytes with the unique capacity for killing NK-resistant fresh human tumor cells in short-term assays. LAK kill autologous as well as allogeneic tumors with complete cross-reactivity. Initial studies on the classification of LAK conclude that LAK are distinct from the classical NK and T lymphocyte systems, based on a number of criteria including surface phenotype, activation conditions, and a spectrum of susceptible target cells. LAK kill ras oncogene-transfected fibroblasts like they kill fresh tumors. As yet, the target cell determinant responsible for susceptibility to LAK lysis is unknown. Activation of LAK requires only IL 2 and is blocked by monoclonal antibodies to the IL 2 receptor. Because only IL 2 alone is sufficient for LAK activation, we have done in vitro testing to determine whether fresh PBL could be activated in the presence of tumor, as might be desirable in vivo. LAK were activated sufficiently to mediate significant destruction of fresh tumor. We also tested whether LAK could be maintained in the presence of large tumors, providing IL 2 was added. Again, results were positive, suggesting that LAK either recycle or are a self-renewing population that depend on IL 2 for continued functions. Because of these and other findings, we have initiated a clinical protocol to test whether LAK made from the PBL of patients with brain tumor could eliminate residual glioma tumor cells. Autologous LAK plus rIL 2 to maintain lytic ability are injected during surgery. Preclinical studies in a rat glioma model have shown this approach to be safe, and previous in vivo murine studies have concluded that LAK kill tumors in Winn-type lung colony formation tests (Kedar et al. 1982). Much work is needed before we can understand the LAK phenomenon and determine its usefulness in cancer therapy, as well as its inherent biologic role. We hope that this chapter will stimulate both interest and the basic research needed to realize LAK potential.","PeriodicalId":77905,"journal":{"name":"Symposium on Fundamental Cancer Research","volume":"38 ","pages":"209-19"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14613009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lymphokine regulation of polyclonal and antigen-specific B cell responses. 多克隆和抗原特异性B细胞反应的淋巴因子调控。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

M Howard, P Stein, P Dubois

引用次数: 0

Development of monoclonal antibodies reactive with the product of the neu oncogene. 与新癌基因产物反应的单克隆抗体的研制。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

J A Drebin, V C Link, D F Stern, R A Weinberg, M I Greene

引用次数: 0

Macrophage recognition of self from nonself: implications for the interaction of macrophages with neoplastic cells. 巨噬细胞从非我中识别自我:巨噬细胞与肿瘤细胞相互作用的意义。

Symposium on Fundamental Cancer Research Pub Date : 1986-01-01

I J Fidler, A J Schroit

引用次数: 0